BTIG Starts Juno Therapeutics (JUNO) at Sell

August 30, 2016 5:28 PM EDT
Get Alerts JUNO Hot Sheet
Price: $28.47 +3.87%

Rating Summary:
    10 Buy, 3 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade JUNO Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

BTIG initiated coverage on Juno Therapeutics (NASDAQ: JUNO) with a Sell rating and a price target of $23, implying downside of 28%. Analyst Dane Leone pointed out that the company's timeline trails competition.

"We are generally skeptical of current investor expectations for the CD19 CAR T market, given the limited datasets and potential competition from CD19 bi-specific antibodies. Our CD19 CAR T market model is below consensus sales expectations out to 2025E, and we are also below consensus revenue expectations for Juno specifically. Our Fair Value analysis for Juno supports a stock price of $23 per share, or ~28% below the current share price," said the analyst.

The analyst added, "Juno has the most robust CD19 CAR T datasets amongst its competitors, Kite (KITE, Neutral) and Novartis (NVS, Not Rated), but the company is behind timelines of both competitors for regulatory approval and commercialization. We expect ASH 2016 (December) to be a key stock catalyst, as Kite and Novartis may present their first pivotal CD19 datasets along with first data for JNJ’s (Johnson & Johnson, Neutral) CD19 bi-specific antibody."

For an analyst ratings summary and ratings history on Juno Therapeutics click here. For more ratings news on Juno Therapeutics click here.

Shares of Juno Therapeutics closed at $31.81 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Hot New Coverage, New Coverage

Related Entities


Add Your Comment